220 related articles for article (PubMed ID: 35938381)
1. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
[TBL] [Abstract][Full Text] [Related]
3. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Schneider S; Blick G; Burke C; Ward D; Benson P; Felizarta F; Green D; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Patarroyo J; Brogan AP; Oglesby A
Infect Dis Ther; 2024 Apr; 13(4):891-906. PubMed ID: 38570443
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
[TBL] [Abstract][Full Text] [Related]
7. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
[TBL] [Abstract][Full Text] [Related]
8. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
Punekar YS; Parks D; Joshi M; Kaur S; Evitt L; Chounta V; Radford M; Jha D; Ferrante S; Sharma S; Van Wyk J; de Ruiter A
HIV Med; 2021 Jul; 22(6):423-433. PubMed ID: 33529489
[TBL] [Abstract][Full Text] [Related]
10. Real world use of dolutegravir two drug regimens.
Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
[TBL] [Abstract][Full Text] [Related]
11. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Ho S; Wong JG; Ng OT; Lee CC; Leo YS; Lye DCB; Wong CS
AIDS Res Ther; 2020 May; 17(1):23. PubMed ID: 32438914
[TBL] [Abstract][Full Text] [Related]
13. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV.
Ramos-Ruperto L; Arcos-Rueda MDM; de Miguel-Buckley R; Busca-Arenzana C; Mican R; Montejano R; Delgado-Hierro A; Montes ML; Valencia ME; Serrano L; Arribas JR; González J; Bernardino JI; Martín-Carbonero L
HIV Med; 2024 Jun; 25(6):684-691. PubMed ID: 38379338
[TBL] [Abstract][Full Text] [Related]
15. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
[TBL] [Abstract][Full Text] [Related]
16. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
19. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
Chang HM; Chou CH; Tsai HC
BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Florence E; Yombi JC; Henrard S; Darcis G; Van Praet J; Vandekerckhove L; Allard SD; Demeester R; Messiaen P; Ausselet N; Delforge M; De Wit S;
HIV Med; 2023 Aug; 24(8):914-924. PubMed ID: 37038245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]